Expanding Applications for Intravenous Platelet Inhibition

Monday, May 20, 2019: 11:15 AM-12:15 PM
Gracia 8 (The Cosmopolitan of Las Vegas)

Supported By: Chiesi

Sponsored By:

The decision to use P2Y12 Inhibitors has been the cornerstone treatment of patients with acute coronary syndrome (ACS). Through case presentations, find out about optimal anti-platelet coverage in patients with ACS and complex stable CAD and the pharmacotherapy treatments. Gain valuable insight into the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Plus, learn vital tips from experts in the field to help you with the transition to oral P2Y12 receptor blockades.
11:15 AM
Intravenous Platelet Inhibition for PCI: Who Are the High-Risk Patients?
Gregg W. Stone, M.D., FSCAI, Cardiovascular Research Foundation
11:27 AM
Roundtable Discussion With Audience Q&A
11:30 AM
Intravenous Platelet Inhibition for PCI and Bridging: Duration, Oral Drug Conversion, and More
George D. Dangas, M.D., Ph.D., MSCAI, Mount Sinai Medical Center
11:42 AM
Roundtable Discussion With Audience Q&A
11:45 AM
Case #1 (With Discussion): Intravenous Platelet Inhibition During PCI in ACS
Deepak L. Bhatt, M.D., FSCAI, Brigham And Women's Hospital
11:55 AM
Case #2 (With Discussion): Intravenous Platelet Inhibition During PCI in Complex Stable CAD
Matthew J. Price, M.D., Scripps Clinic
12:05 PM
Case #3 (With Discussion): Intravenous Platelet Inhibition for Bridging
Eric A. Osborn, M.D., Ph.D., FSCAI, Beth Israel Deaconess Medical Center
See more of: Satellite Sessions
<< Previous Satellite | Next Satellite >>